MX344925B - Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas. - Google Patents
Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas.Info
- Publication number
- MX344925B MX344925B MX2013009948A MX2013009948A MX344925B MX 344925 B MX344925 B MX 344925B MX 2013009948 A MX2013009948 A MX 2013009948A MX 2013009948 A MX2013009948 A MX 2013009948A MX 344925 B MX344925 B MX 344925B
- Authority
- MX
- Mexico
- Prior art keywords
- chromium
- insulin
- hypoglycemia
- prevention
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
La presente invención se refiere a una composición que comprende cromo e insulina y/o un complejo de cromo-insulina, su método de preparación y su uso en la prevención y tratamiento de hipoglucemia y condiciones relacionadas con hipoglucemia. Esta composición puede ser administrada de numerosas maneras, incluyendo parental, intranasal y oralmente. La composición estabiliza los niveles de glucosa en el suero y tiene efecto sinergista en comparación con cromo e insulina administrados separadamente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161448134P | 2011-03-01 | 2011-03-01 | |
PCT/US2012/027342 WO2012119007A1 (en) | 2011-03-01 | 2012-03-01 | Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013009948A MX2013009948A (es) | 2014-03-27 |
MX344925B true MX344925B (es) | 2017-01-11 |
Family
ID=45841644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013009948A MX344925B (es) | 2011-03-01 | 2012-03-01 | Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas. |
Country Status (11)
Country | Link |
---|---|
US (2) | US8933022B2 (es) |
EP (2) | EP4070801A1 (es) |
JP (1) | JP6152346B2 (es) |
KR (1) | KR101836957B1 (es) |
CN (2) | CN103702672B (es) |
AU (1) | AU2012223282B2 (es) |
CA (1) | CA2828572C (es) |
ES (1) | ES2927800T3 (es) |
IL (1) | IL228209B (es) |
MX (1) | MX344925B (es) |
WO (1) | WO2012119007A1 (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1969004E (pt) | 2005-12-28 | 2011-11-25 | Novo Nordisk As | Composições que compreendem uma insulina acilada e zinco e método para criar tais composições |
PL3050568T3 (pl) | 2007-03-13 | 2021-06-14 | Jds Therapeutics, Llc | Sposoby i kompozycje do przedłużonego uwalniania chromu |
WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
US7959598B2 (en) | 2008-08-20 | 2011-06-14 | Asante Solutions, Inc. | Infusion pump systems and methods |
US20110313680A1 (en) * | 2010-06-22 | 2011-12-22 | Doyle Iii Francis J | Health Monitoring System |
DK2632478T3 (da) | 2010-10-27 | 2019-10-07 | Novo Nordisk As | Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller |
US8543505B2 (en) | 2011-01-14 | 2013-09-24 | Federal Law Enforcement Development Services, Inc. | Method of providing lumens and tracking of lumen consumption |
US8933022B2 (en) | 2011-03-01 | 2015-01-13 | Jds Therapeutics, Llc | Methods and compositions for the treatment and prevention Hypoglycemia and related disorders |
US20160296602A1 (en) * | 2013-03-20 | 2016-10-13 | Novo Nordisk A/S | Dosing Regimen |
EP2991672A1 (en) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
GB2523989B (en) | 2014-01-30 | 2020-07-29 | Insulet Netherlands B V | Therapeutic product delivery system and method of pairing |
US10737024B2 (en) | 2015-02-18 | 2020-08-11 | Insulet Corporation | Fluid delivery and infusion devices, and methods of use thereof |
EP3374905A1 (en) | 2016-01-13 | 2018-09-19 | Bigfoot Biomedical, Inc. | User interface for diabetes management system |
CN112933333B (zh) | 2016-01-14 | 2023-03-28 | 比格福特生物医药公司 | 调整胰岛素输送速率 |
US11865121B2 (en) | 2016-02-11 | 2024-01-09 | Nutrition21, LLC | Chromium containing compositions for improving health and fitness |
US20190201494A1 (en) * | 2016-09-13 | 2019-07-04 | Stc Unm | Compositions and methods for treating nicotine withdrawal |
EP3515535A1 (en) | 2016-09-23 | 2019-07-31 | Insulet Corporation | Fluid delivery device with sensor |
USD928199S1 (en) | 2018-04-02 | 2021-08-17 | Bigfoot Biomedical, Inc. | Medication delivery device with icons |
JP7124120B2 (ja) | 2018-05-04 | 2022-08-23 | インスレット コーポレイション | 制御アルゴリズムベースの薬物送達システムのための安全制約 |
US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
EP3856285A1 (en) | 2018-09-28 | 2021-08-04 | Insulet Corporation | Activity mode for artificial pancreas system |
EP3864668A1 (en) | 2018-10-11 | 2021-08-18 | Insulet Corporation | Event detection for drug delivery system |
US11801344B2 (en) | 2019-09-13 | 2023-10-31 | Insulet Corporation | Blood glucose rate of change modulation of meal and correction insulin bolus quantity |
US11935637B2 (en) | 2019-09-27 | 2024-03-19 | Insulet Corporation | Onboarding and total daily insulin adaptivity |
WO2021113647A1 (en) | 2019-12-06 | 2021-06-10 | Insulet Corporation | Techniques and devices providing adaptivity and personalization in diabetes treatment |
AU2020407071A1 (en) | 2019-12-16 | 2022-07-07 | Nutrition 21, Llc | Methods of production of arginine-silicate complexes |
US11833329B2 (en) | 2019-12-20 | 2023-12-05 | Insulet Corporation | Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns |
US11551802B2 (en) | 2020-02-11 | 2023-01-10 | Insulet Corporation | Early meal detection and calorie intake detection |
US11547800B2 (en) | 2020-02-12 | 2023-01-10 | Insulet Corporation | User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system |
US11324889B2 (en) | 2020-02-14 | 2022-05-10 | Insulet Corporation | Compensation for missing readings from a glucose monitor in an automated insulin delivery system |
US11607493B2 (en) | 2020-04-06 | 2023-03-21 | Insulet Corporation | Initial total daily insulin setting for user onboarding |
US11684716B2 (en) | 2020-07-31 | 2023-06-27 | Insulet Corporation | Techniques to reduce risk of occlusions in drug delivery systems |
US11904140B2 (en) | 2021-03-10 | 2024-02-20 | Insulet Corporation | Adaptable asymmetric medicament cost component in a control system for medicament delivery |
US11738144B2 (en) | 2021-09-27 | 2023-08-29 | Insulet Corporation | Techniques enabling adaptation of parameters in aid systems by user input |
US11439754B1 (en) | 2021-12-01 | 2022-09-13 | Insulet Corporation | Optimizing embedded formulations for drug delivery |
WO2023212165A1 (en) | 2022-04-27 | 2023-11-02 | Afton Chemical Corporation | Additives with high sulfurization for lubricating oil compositions |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK135268A (es) | 1973-02-09 | |||
US4164573A (en) | 1975-06-13 | 1979-08-14 | Galinsky Alvin M | Composition and method for making a suppository for introducing a hypoglycemic agent into a mammal |
EP0016496B1 (en) | 1979-03-19 | 1983-10-19 | THE PROCTER & GAMBLE COMPANY | Chromium acetylacetonate as a dietary supplement and pharmaceutical agent |
US4421685A (en) | 1980-03-27 | 1983-12-20 | Eli Lilly And Company | Process for producing an insulin |
USRE33988E (en) | 1980-08-08 | 1992-07-07 | The United States of America as repesented by the Secretary of Agriculture | Dietary supplementation with essential metal picolinates |
US4315927A (en) | 1980-08-08 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Dietary supplementation with essential metal picolinates |
FI78616C (fi) | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
US4424057A (en) | 1982-04-01 | 1984-01-03 | House Hugh A | Wet-dry syringe |
US4954492A (en) | 1983-07-08 | 1990-09-04 | The William Seroy Group | Synthetic GTF chromium material for decreasing blood lipid levels and process therefor |
US5194615A (en) | 1983-07-08 | 1993-03-16 | The William Seroy Group | Synthetic GTF chromium nicotinate material and its preparation |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5731303A (en) | 1985-12-04 | 1998-03-24 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery compositions |
DK179286D0 (da) | 1986-04-18 | 1986-04-18 | Nordisk Gentofte | Insulinpraeparat |
US5175156A (en) | 1987-11-30 | 1992-12-29 | Nutrition 21 | Chromic picolinate treatment |
US5087623A (en) | 1988-05-31 | 1992-02-11 | Nitrition 21 | Chromic picolinate treatment |
US5085996A (en) | 1988-07-29 | 1992-02-04 | Evans Gary W | Microorganism growth acceleration medium containing an effective amount of picolinic acid or metal picolinate to promote growth of the microorganism |
US5057320A (en) | 1988-08-01 | 1991-10-15 | Nutrition 21 | Means and method for increasing skin respiration |
US6140304A (en) | 1988-09-28 | 2000-10-31 | Eicotech Corporation | Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia |
US5087624A (en) | 1989-03-21 | 1992-02-11 | Nutrition 21 | Chromic picolinate treatment |
WO1991011117A2 (en) | 1990-02-05 | 1991-08-08 | Board Of Regents, The University Of Texas System | Dietary supplements comprising vitamins and minerals |
US6099856A (en) | 1992-06-15 | 2000-08-08 | Emisphere Technologies, Inc. | Active agent transport systems |
US5629020A (en) | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
US5164384A (en) | 1991-06-19 | 1992-11-17 | Metagenics, Inc. | Anabolic mineral formula |
US5336672A (en) | 1992-07-21 | 1994-08-09 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Increasing egg production in poultry |
SE9203753D0 (sv) | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
CA2160693C (en) | 1993-04-22 | 2010-03-16 | Sam J. Milstein | Oral drug delivery compositions and methods |
US5643957A (en) | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5534488A (en) | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
US5496827A (en) | 1994-07-15 | 1996-03-05 | Patrick; Jay | Compositions for the transdermal delivery of nutrients |
US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
US6001347A (en) | 1995-03-31 | 1999-12-14 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5965121A (en) | 1995-03-31 | 1999-10-12 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5989539A (en) | 1995-03-31 | 1999-11-23 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
BR9604880A (pt) | 1995-03-31 | 1998-05-19 | Emisphere Tech Inc | Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica |
US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6090958A (en) | 1995-03-31 | 2000-07-18 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6099869A (en) | 1995-04-18 | 2000-08-08 | Nutrition 21 | Calcium taurate and antihypertensive drug for hypertension |
US5776498A (en) | 1995-11-06 | 1998-07-07 | Nutrition 21 | Magnesium taurate as an adjuvant to rapid thrombolytic therapy |
US5582839A (en) | 1995-04-18 | 1996-12-10 | Nutrition 21 | Magnesium taurate and other mineral taurates |
US6329361B1 (en) | 1995-05-12 | 2001-12-11 | Nutrition 21 | High-dose chromic picolinate treatment of type II diabetes |
US5597585A (en) | 1995-12-26 | 1997-01-28 | Williams; Andrew H. | Vitamin/mineral composition |
US5635535A (en) | 1996-04-05 | 1997-06-03 | Wagstaff; Robert K. | Method for increasing blood glucose levels |
US6060513A (en) | 1997-02-07 | 2000-05-09 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5879681A (en) | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
US5990166A (en) | 1997-02-07 | 1999-11-23 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5876710A (en) | 1997-02-07 | 1999-03-02 | Emisphere Technologies Inc. | Compounds and compositions for delivering active agents |
US5939381A (en) | 1997-02-07 | 1999-08-17 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6358504B1 (en) | 1997-02-07 | 2002-03-19 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6051561A (en) | 1997-02-07 | 2000-04-18 | Emisphere Technologies Inc. | Compounds and compositions for delivering active agents |
US5804688A (en) | 1997-02-07 | 1998-09-08 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5776888A (en) | 1997-02-07 | 1998-07-07 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5707970A (en) | 1997-02-12 | 1998-01-13 | Nutrition 21 | Arginine silicate complex and use thereof |
US6291495B1 (en) * | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
US5863944A (en) | 1997-04-30 | 1999-01-26 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
DE19722618A1 (de) | 1997-05-30 | 1998-12-03 | Philips Patentverwaltung | Hochtemperaturkondensator |
US5789401A (en) | 1997-08-08 | 1998-08-04 | Nutrition 21 | High-dose chromium/biotin treatment of type II diabetes |
US5914326A (en) | 1997-08-08 | 1999-06-22 | Ambi Inc. | Method for promoting weight and fat loss |
ATE304364T1 (de) | 1997-08-08 | 2005-09-15 | Nutrition 21 | Chromium/biotin behandlung von typ-ii diabetes |
US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6048846A (en) | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
US6245027B1 (en) | 1998-04-10 | 2001-06-12 | Noam Alperin | Method of measuring intracranial pressure |
US5948772A (en) | 1998-08-28 | 1999-09-07 | Ambi Inc. | Chromium picolinate compositions and uses thereof |
NZ509239A (en) | 1998-07-27 | 2002-10-25 | Emisphere Tech Inc | 2-(4-(N-salicyloyl)aminophenyl)propionic acid useful as a carrier in compositions for delivering active agents |
HUP0103188A2 (hu) | 1998-08-07 | 2001-12-28 | Emisphere Technologies, Inc. | Vegyületek és készítmények hatóanyagok célbajuttatására |
US5980905A (en) | 1998-08-28 | 1999-11-09 | Ambi Inc. | Chromium polynicotinate compositions and uses thereof |
US6376549B1 (en) * | 1998-09-17 | 2002-04-23 | Akesis Pharmaceuticals, Inc. | Metforimin-containing compositions for the treatment of diabetes |
CA2344246A1 (en) * | 1998-09-17 | 2000-03-23 | Akesis Pharmaceuticals, Inc. | Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders |
JP4854855B2 (ja) | 1999-02-11 | 2012-01-18 | エミスフェアー・テクノロジーズ・インク | オキサジアゾール化合物及び活性剤をデリバリーするための組成物 |
MXPA01008611A (es) | 1999-02-26 | 2003-06-24 | Emisphere Tech Inc | Compuestos y composiciones para suministrar agentes activos. |
EP1175390B1 (en) | 1999-04-05 | 2005-02-02 | Emisphere Technologies, Inc. | Disodium salts, monohydrates, and ethanol solvates |
US6261606B1 (en) * | 1999-09-14 | 2001-07-17 | Natural Compounds, Ltd. | Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
JP2001104702A (ja) | 1999-10-01 | 2001-04-17 | Air Liquide Japan Ltd | ガスの集合回収装置および集合回収方法 |
DE19948361A1 (de) | 1999-10-07 | 2001-04-12 | Bsh Bosch Siemens Hausgeraete | Kältegerät |
US6689383B1 (en) | 1999-10-08 | 2004-02-10 | The United States Of America As Represented By The Secretary Of Agriculture | Chromium-histidine complexes as nutrient supplements |
CA2390025A1 (en) | 1999-11-05 | 2001-05-10 | Emisphere Technologies, Inc. | Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
WO2001034114A1 (en) | 1999-11-12 | 2001-05-17 | Emisphere Technologies, Inc. | Liquid heparin formulation |
DE19959351A1 (de) | 1999-12-09 | 2001-06-13 | Bilstein Spezialfab Wilhelm | Schneidvorrichtung mit Eigenantrieb für eine Einrichtung zum Längsteilen von durchlaufenden Materialbahnen |
AU2274201A (en) | 1999-12-16 | 2001-06-25 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
WO2001051454A1 (en) | 2000-01-13 | 2001-07-19 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
CN100482637C (zh) | 2000-06-29 | 2009-04-29 | 艾米斯菲尔技术有限公司 | 用于投递活性剂的化合物和组合物 |
US6365176B1 (en) | 2000-08-08 | 2002-04-02 | Functional Foods, Inc. | Nutritional supplement for patients with type 2 diabetes mellitus for lipodystrophy |
JP5089845B2 (ja) | 2000-09-06 | 2012-12-05 | エミスフェアー・テクノロジーズ・インク | シアノフェノキシカルボン酸化合物および活性薬剤送達用組成物 |
DE60134245D1 (de) | 2000-09-06 | 2008-07-10 | Emisphere Tech Inc | (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten |
JP2004509143A (ja) | 2000-09-21 | 2004-03-25 | ニュートリション 21、インコーポレイテッド | クロム錯体、共役脂肪酸及び/又は共役脂肪アルコールによる糖尿病の治療、体脂肪減少、インシュリン感受性の改善、高血糖症軽減及び高コレステロール血症軽減の方法及び組成物 |
US20020086065A1 (en) | 2000-10-31 | 2002-07-04 | Katz David P. | Methods and compositions for the benefit of those suffering from polycystic ovary syndrome with chromium complexes |
WO2002036202A2 (en) | 2000-11-02 | 2002-05-10 | Nutrition 21, Inc. | Methods and compositions for the improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes and alpha lipoic acid |
ATE339961T1 (de) | 2001-02-27 | 2006-10-15 | Nutrition 21 Inc | Chromium/biotin behandlung von dyslipidemia |
NZ527157A (en) | 2001-03-01 | 2005-04-29 | Emisphere Tech Inc | Compositions for delivering bisphosphonates |
CN1494420A (zh) | 2001-03-01 | 2004-05-05 | 埃米斯菲尔技术公司 | 释放活性成分的化合物和组合物 |
WO2003043569A2 (en) | 2001-11-16 | 2003-05-30 | Nutrition 21, Inc. | Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases |
US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
MXPA04010392A (es) | 2002-04-23 | 2005-08-18 | Nutrition 21 Inc | Composiciones de cromo y metodos para utilizar las mismas para inhibir resistencia a insulina inducida por droga. |
US7063865B2 (en) | 2002-05-10 | 2006-06-20 | Jeremy Park Jones | Composition and method for substantially reducing the deleterious effects of alcohol on the body |
US20040005368A1 (en) | 2002-07-01 | 2004-01-08 | Morris Mann | Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite |
US7291591B2 (en) | 2003-04-11 | 2007-11-06 | All Natural Fmg, Inc. | Alcohol-free transdermal insulin composition |
OA13177A (en) | 2003-06-04 | 2006-12-13 | Willem Jacob Serfontein | Nutritional compositions and use thereof. |
US20050069593A1 (en) | 2003-09-29 | 2005-03-31 | Life Time Fitness, Inc. | Nutritional supplement containing 7-Keto-DHEA and conjugated linoleic acid |
NZ547587A (en) | 2003-12-08 | 2009-09-25 | Cpex Pharmaceuticals Inc | Pharmaceutical compositions and methods for insulin treatment |
US20060024383A1 (en) | 2004-07-27 | 2006-02-02 | Roger Berlin | Compositions containing policosanol and chromium and/or chromium salts and their pharmaceutical uses |
AU2005311601B2 (en) * | 2004-12-03 | 2011-12-01 | Rhode Island Hospital | Diagnosis and treatment of Alzheimer's Disease |
WO2008094939A1 (en) | 2007-01-31 | 2008-08-07 | Nutrition 21, Inc. | Use of chromium histidinate for treatment of cardiometabolic disorders |
PL3050568T3 (pl) | 2007-03-13 | 2021-06-14 | Jds Therapeutics, Llc | Sposoby i kompozycje do przedłużonego uwalniania chromu |
WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
US20100262434A1 (en) | 2007-12-13 | 2010-10-14 | Shaya Steven A | Method and apparatus to calculate diabetic sensitivity factors affecting blood glucose |
EP3513790A1 (en) | 2009-07-01 | 2019-07-24 | JDS Therapeutics, LLC | Chromium complexes as enhancers of brain glucose transporters |
US8933022B2 (en) | 2011-03-01 | 2015-01-13 | Jds Therapeutics, Llc | Methods and compositions for the treatment and prevention Hypoglycemia and related disorders |
-
2012
- 2012-03-01 US US13/409,960 patent/US8933022B2/en active Active
- 2012-03-01 CN CN201280020399.9A patent/CN103702672B/zh not_active Expired - Fee Related
- 2012-03-01 CN CN201610172098.8A patent/CN105749253A/zh active Pending
- 2012-03-01 AU AU2012223282A patent/AU2012223282B2/en not_active Ceased
- 2012-03-01 MX MX2013009948A patent/MX344925B/es active IP Right Grant
- 2012-03-01 WO PCT/US2012/027342 patent/WO2012119007A1/en active Application Filing
- 2012-03-01 CA CA2828572A patent/CA2828572C/en active Active
- 2012-03-01 JP JP2013556874A patent/JP6152346B2/ja not_active Expired - Fee Related
- 2012-03-01 KR KR1020137025794A patent/KR101836957B1/ko active IP Right Grant
- 2012-03-01 ES ES12709222T patent/ES2927800T3/es active Active
- 2012-03-01 EP EP22160569.4A patent/EP4070801A1/en not_active Withdrawn
- 2012-03-01 EP EP12709222.9A patent/EP2680861B1/en active Active
-
2013
- 2013-08-29 IL IL228209A patent/IL228209B/en active IP Right Grant
-
2014
- 2014-12-08 US US14/563,783 patent/US20150094258A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2012223282B2 (en) | 2017-02-02 |
IL228209B (en) | 2020-05-31 |
MX2013009948A (es) | 2014-03-27 |
KR20140023298A (ko) | 2014-02-26 |
AU2012223282A1 (en) | 2013-09-19 |
EP2680861B1 (en) | 2022-05-04 |
CA2828572C (en) | 2021-02-23 |
JP2014506932A (ja) | 2014-03-20 |
CN103702672A (zh) | 2014-04-02 |
CA2828572A1 (en) | 2012-09-07 |
EP2680861A1 (en) | 2014-01-08 |
JP6152346B2 (ja) | 2017-06-21 |
KR101836957B1 (ko) | 2018-03-09 |
US20120225134A1 (en) | 2012-09-06 |
CN105749253A (zh) | 2016-07-13 |
CN103702672B (zh) | 2016-04-27 |
US8933022B2 (en) | 2015-01-13 |
EP4070801A1 (en) | 2022-10-12 |
ES2927800T3 (es) | 2022-11-11 |
WO2012119007A1 (en) | 2012-09-07 |
US20150094258A1 (en) | 2015-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX344925B (es) | Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas. | |
PH12015501291A1 (en) | Functionalized exendin-4 derivatives | |
WO2013186240A3 (en) | Exendin-4 peptide analogues | |
PH12015500688A1 (en) | Exendin-4 derivatives as dual glp1/glucagon agonists | |
MY176863A (en) | Ibat inhibitors for treatment of metabolic disorders and related conditions | |
MX2013004699A (es) | Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos. | |
HUE043540T2 (hu) | Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben | |
EP2621282A4 (en) | GABA AGONISTS FOR THE TREATMENT OF DISEASES RELATED TO THE METABOLIC SYNDROME AND GABA COMBINATIONS FOR THE TREATMENT OR PROPHYLAXIS OF DIABETES TYPE I | |
WO2013158928A3 (en) | Chemosensory receptor ligand-based therapies | |
BR112014000380A2 (pt) | composição farmacêutica, métodos para tratamento e usos dos mesmos | |
MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
MY153062A (en) | Methods of treating gastrointestinal disorders independent of the intake of food | |
PT2691109E (pt) | Prevenção de hipoglicemia em pacientes com diabetes mellitus tipo 2 | |
MX2013011124A (es) | Compuestos para el tratamiento del sindrome metabolico. | |
WO2015003122A3 (en) | Regulation of glucose metabolism using anti-cgrp antibodies | |
WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
IN2012DN00549A (es) | ||
MX2013012967A (es) | Composicion de miel con l-alanil-l-glutamina. | |
WO2014018763A3 (en) | Method of treating type i diabetes using apolipoprotein aiv | |
WO2014014819A3 (en) | Methods of treating glucose metabolism disorders | |
WO2013090319A3 (en) | Treatment of type i and type ii diabetes | |
WO2012004416A3 (en) | Treatment of a disease associated with retinal degenerative disorder | |
EA201490712A1 (ru) | Синергетическая травяная композиция для профилактики и лечения диабетической ретинопатии и катаракты | |
TN2013000187A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
MX2015017136A (es) | Composicion para la administracion oral de magnesio, en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |